PD-1 Blockade-activated Neoantigen Specific Cellular Therapy For Advanced Relapsed Non Small Cell Lung Cancer

Background Due to its strong immunogenicity and tumor specificity, neoplastic antigen has emerged as an immunotherapy target with wide therapeutic prospect and clinical application value. Anti-programmed death-1 (PD-1) antibodies reinvigorate T cell-mediated antitumor immunity .So we conducted single-arm trial to assess the safety and efficacy of PD-1 blockade(Camrelizumab)-activated Neoantigen Specific Cellular Therapy (aNASCT) on advanced relapsed non-small lung cancer( NSCLC)(ClinicalTrials.gov NCT03205930). Methods Neoantigenic peptides were designed and manufactured according to the whole-exome sequencing and RNA sequencing of fresh biopsy tissues and peripheral blood as well as bioinformatics analysis.All participants received subcutaneous injection of mature DCS (mDCS) loaded with neoantigens on day 8 and subcutaneous injection of mDC-induced autologous somatic toxic T lymphocytes (CTLS) on day 27 for a period defined as 28 days (4 weeks). Enrolled patients received at least 3 cycles of therapy.The safety and efficacy of the treatment were evaluated by evaluating adverse reactions, progression-free survival (PFS), overall survival (OS). Results A total of 13 patients with advanced replased NSCLC were enrolled in this study. All 13 patients received at least 3 cycles of aNASCT treatment, of which 2 patients received at most 12 cycles of treatment. Treatment-related adverse events (AEs) occurred in 4/13 (30.8%)patients with transient fever below 38℃.The objective response rate (ORR) across the 13 enrolled patients was 7 of 13 (53.85%).The disease control rate (DCR) was 8 of 13 (61.54%). The median PFS was 11 months (95% CI 6.1–15.9), and the median OS was 15 months(95% CI 11.5–18.5). Conclusions Our findings indicate that aMASCT therapy was safety and immunogenicity of patients with advanced relapsed NSCLC, suggesting its promising potential in cancer immunotherapy.